Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Sexual Dysfunctions, Psychological 1Breast Neoplasms 1

Interventions

Specimen Handling 22Magnetic Resonance Spectroscopy 20Carboplatin 17Gemcitabine 15pembrolizumab 13Cisplatin 13Paclitaxel 12Injections 11Interviews as Topic 10fludarabine 9Radiotherapy 9Cyclophosphamide 9Oxaliplatin 8Dexamethasone 8Biopsy 8Bevacizumab 8toripalimab 7Nivolumab 7Irinotecan 7Fluorouracil 7Bortezomib 7X-Rays 6Radiosurgery 6Pemetrexed 6Leucovorin 6Capecitabine 6durvalumab 5cemiplimab 5anlotinib 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Leuprolide × 30 days × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

Data powered by HemOnc (CC BY 4.0) Colophon âš¡